rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Biofrontera Inc.

BFRI · Nasdaq

Health CareBiotechnologyNot moving yet

BFRI stood above a rising 150-day average in 23 of the last 52 weekly readings, and has been out of that trend for the last 3 weeks. It is 24.4% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 3
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
17 (+5)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 23 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$1$0$1Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders17+5 on the quarter
New · exited7 · 2
Reported value$2.6M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Rosalind Advisors, Inc.added · filed 14 Aug 20261,275,609$1.2M+111,647+9.6%
AIGH Capital Management LLCreduced · filed 7 Aug 2026739,910$700K-175,300−19.2%
RENAISSANCE TECHNOLOGIES LLCnew · filed 13 Aug 2026157,505$149K+157,505
CITADEL ADVISORS LLCnew · filed 14 Aug 2026104,941$99K+104,941
JANE STREET GROUP, LLCnew · filed 14 Aug 202693,000$88K+93,000
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 202676,689$73K-32,611−29.8%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 202671,380$68K+19,126+36.6%
VANGUARD FIDUCIARY TRUST COunchanged · filed 13 Aug 202661,697$58K00.0%
XTX Topco Ltdadded · filed 14 Aug 202651,894$49K+29,401+130.7%
NORTHERN TRUST CORPnew · filed 13 Aug 202631,536$30K+31,536
30 Sep 2023 – 30 Jun 2026
61217Sep 23Jun 24Mar 25Sep 25Jun 26

Everyone who traded it

Eugene Frederick Leffler Company insiderChief Financial Officer · last 28 Jul 20260 · 0
Hermann Luebbert Company insiderCEO & Chairman · last 28 Jul 20260 · 0
Beth J. Hoffman Company insiderDirector · last 4 Mar 20260 · 0
George Patrick Jones Company insiderChief Commercial Officer · last 4 Mar 20260 · 0
Heikki Lanckriet Company insiderDirector · last 4 Mar 20260 · 0
John J. Borer III Company insiderDirector · last 4 Mar 20260 · 0
Kevin Daniel Weber Company insiderDirector · last 4 Mar 20260 · 0
Ag Biofrontera Company insiderDirector, 10% owner · last 16 Sep 20250 · 0
Erica L. Monaco Company insiderChief Executive Officer · last 18 May 20230 · 0
Erica F. Gates Company insiderSenior Director Finance · last 18 May 20220 · 0
Loretta M. Wedge Company insiderDirector · last 18 May 20220 · 0

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Operating profit marginFY 2025 · to 31 Dec 2025-27.2%
Free cash flow marginFY 2025 · to 31 Dec 2025-32.0%
Return on capital employedFY 2025 · to 31 Dec 2025-68.1%
Research spendFY 2025 · to 31 Dec 20258.9%
Share count trendFY 2025 · to 16 Mar 20260.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$6.4M
Free cash flowFY 2025 · to 31 Dec 2025−$13.4M

Analyst forecasts

No analyst forecasts yet.